UK Markets close in 7 hrs 29 mins

Valneva SE (0OB3.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
5.58-0.13 (-2.33%)
As of 08:36AM BST. Market open.

Yahoo Finance will soon be upgrading our Conversations message board platform to provide a better experience for our users. Only comments published since April 21, 2021 will be visible on Yahoo Finance after the upgrade. If you wish to download and save any of your older comments, please submit a request via the Privacy Dashboard by no later than Sept. 30.

Sign in to post a message.
  • D
    Dennis
    Dr. Aseem Malhotra. Political Advisor for many countries including USA. Says no to MRNA Jabs
    Dr. Aseem Malhotra. (Courtesy of Dr. Aseem Malhotra)
    Vaccines & Safety
    Doctor Turns Against Messenger RNA COVID-19 Vaccines, Calls for Global Pause
    By Zachary Stieber and Jan Jekielek
    September 26, 2022 Updated: September 26, 2022

    A doctor who promoted COVID-19 vaccines is now calling for health authorities around the world to pause administration of two of the most-widely utilized COVID-19 vaccines, asserting that the benefits from the vaccines may not outweigh the risks.

    “There is more than enough evidence—I would say the evidence is overwhelming—to pause the rollout of the vaccine,” Dr. Aseem Malhotra, a British cardiologist and evidence-based medicine expert, told The Epoch Times.
  • m
    marc
    They are advertising for participants in the Lyme trial on Pandora. That was fast
  • M
    Marcelino
    You can answer whatever you want.
    But not that I have not warned you
  • M
    Marcelino
    Marcelino 5 months ago
    VLA.PA conversation
    Cash burner will go down to 5 Euro when the market goes down
  • M
    Marcelino
    Bet won.
    Within 14 days on 8 Éuros
    I told you 12 days ago
  • f
    fomostocks
    (VAXX) $2.35 ..Potential BEST Vaccine for Covid Prevention with final Phase 3 results in early Q4 and a Alzheimer Vaccine which is Phase 2b ready = this could be the biggest opp of ALL Covid stocks ...GLTA
    "The Phase 3 heterologous boost study evaluating UB-612 against COVID-19 in subjects who have received primary immunization from mRNA, adenovirus vector, or inactivated viral vaccines is ongoing. Vaxxinity expects a topline readout in the second half of 2022, and if successful, these data will support global marketing authorization applications."

    ###
  • D
    Dennis
    VALN, Yes , this and NVAX will be the most sought after Vaccines because of safety and effectiveness.
    Who is going to want the MRNA death Vax that do more harm than good. And they don't even work. I know several people that had adverse affects from MRNA tracking VAX's. My Mom developed heart problems after the 2nd dose, so no baloney boosters
  • M
    Marcelino
    My bet in 14 days at the latest to 8 Euros
  • D
    Dennis
    Good news! WHO
    Valneva Confirms WHO Recommendations for its Inactivated COVID-19 Vaccine
    VALNEVA Tue, August 23, 2022 at 8:45 AM
  • t
    thomas
    dead money until lyme catalyst
  • D
    Dennis
    VALN, Can I have this safe Vaccine in America yet?
  • J
    John in emerald isle
    valneva is finished when it comes to covid vaccine. halted production after european deal is miniscule. only hold this stock if you are in for a long wait
  • P
    Play4keeps
    Wow. Very disappointing. JMHO, the price action since the PFE announcement would have told you that there was a lurking omen . I am actually surprised that this was terminated. My guess is the pivot will be to NVAX in Europe and maybe the rest of the world. I’m still trying to figure out what this means for DVAX.

    Regarding Lyme, when there is a bottom in this, VALN will be a good buy. Maybe around 15.

    GL
  • M
    Marcelino
    Dennis was right with *Feeling the next news will be Hugh.*
  • D
    Dennis
    Vaccine will multiply and be fruitful and Valn has other products with revenue increasing exponentially!
    Income Statement
    Currency in EUR. All numbers in thousands
    Get access to 40+ years of historical data with Yahoo Finance Plus Essential.
    Breakdown
    ttm
    12/31/2021
    12/31/2020
    12/31/2019
    12/31/2018
    Total Revenue
    348,085 2021
    348,085
    110,321
    126,196 2020
    113,035
  • H
    Holland
    Can’t find the right stocks to trade? I have the fix for free (http://traderspot.club)
  • D
    Dennis
    normally the street would 👏 applaud the great news we have lately. Only Big Pharma paid shorter etc. would react negatively, So ask the shorter to explain with facts. Same with VALN, the shorts make a false statement and then run with it for day's. right? Big pharm shorty?
    I'm a doctor and have been hoping for a non MRNA Vaccine that does more harm than good.
  • D
    Dennis
    THERE is some BS news that VALN said it will not keep producing their EU "Marketing Approved" Covid 19 vaccine???Send us a dose and all of my friends in need will take it!! Safe as can be. ( no side affects?) I recently saw news on about VALN applying for UAL approval in US and other counties in the new future.Why not? haha, they have full marketing approval for Europe and a couple other countries. Cover shorts and go long before the exelent good news!! Covid 19 is not going away with the MRNA vaccines??Thomas Lingelbach, Chief Executive Officer of Valneva, commented, ?We are extremely pleased that the EC granted full marketing authorization for VLA2001, the only inactivated whole-virus COVID-19 vaccine available in Europe. Once again, we have shown that Valneva has the expertise to bring a vaccine all the way from bench to market. Since we began working on VLA2001, we have continued to receive messages from Europeans who are waiting for a more traditional vaccine technology. Now that we have received this full marketing authorization, we hope that the EC and its member states will place orders that reflect this demand. 15% of Europeans over 18 are not yet vaccinated[1], and we believe that making our inactivated vaccine available could increase vaccination coverage and have a meaningful impact on public health.? Couple weeks ago news: Pursuant to an Equity Subscription Agreement, Pfizer has invested #$%$90.5 ($95) million in Valneva, representing 8.1% of Valneva?s share capital at a price of #$%$9.49 per share, through a reserved capital increase. Valneva is planning to use the proceeds to support its contribution to the planned Phase 3 development program for Lyme disease vaccine candidate VLA15. Pfizer plans to initiate the Phase 3 study of VLA15 in the third quarter of 2022.
  • J
    John in emerald isle
    without any good news of european or UK contracts this stock is slowly bleeding every day. am I missing something ?